Targeting lysophosphatidic acid in cancer: The issues in moving from bench to bedside

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Since the clear demonstration of lysophosphatidic acid (LPA)’s pathological roles in cancer in the mid-1990s, more than 1000 papers relating LPA to various types of cancer were published. Through these studies, LPA was established as a target for cancer. Although LPA-related inhibitors entered clinical trials for fibrosis, the concept of targeting LPA is yet to be moved to clinical cancer treatment. The major challenges that we are facing in moving LPA application from bench to bedside include the intrinsic and complicated metabolic, functional, and signaling properties of LPA, as well as technical issues, which are discussed in this review. Potential strategies and perspectives to improve the translational progress are suggested. Despite these challenges, we are optimistic that LPA blockage, particularly in combination with other agents, is on the horizon to be incorporated into clinical applications.

Original languageEnglish (US)
Article number1523
JournalCancers
Volume11
Issue number10
DOIs
StatePublished - Oct 2019

Fingerprint

Neoplasms
lysophosphatidic acid
Fibrosis
Clinical Trials

Keywords

  • Autotaxin (ATX)
  • Cancer stem cell (CSC)
  • Electrospray ionization tandem mass spectrometry (ESI-MS/MS)
  • G-protein coupled receptor (GPCR)
  • Lipid phosphate phosphatase enzymes (LPPs)
  • Lysophosphatidic acid (LPA)
  • Nuclear receptor peroxisome proliferator-activated receptor (PPAR)
  • Ovarian cancer (OC)
  • Phospholipase A enzymes (PLAs)
  • Sphingosine-1 phosphate (S1P)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting lysophosphatidic acid in cancer : The issues in moving from bench to bedside. / Xu, Yan.

In: Cancers, Vol. 11, No. 10, 1523, 10.2019.

Research output: Contribution to journalReview article

@article{ecdf720eb2624ad2ad6ef0b3811f1547,
title = "Targeting lysophosphatidic acid in cancer: The issues in moving from bench to bedside",
abstract = "Since the clear demonstration of lysophosphatidic acid (LPA)’s pathological roles in cancer in the mid-1990s, more than 1000 papers relating LPA to various types of cancer were published. Through these studies, LPA was established as a target for cancer. Although LPA-related inhibitors entered clinical trials for fibrosis, the concept of targeting LPA is yet to be moved to clinical cancer treatment. The major challenges that we are facing in moving LPA application from bench to bedside include the intrinsic and complicated metabolic, functional, and signaling properties of LPA, as well as technical issues, which are discussed in this review. Potential strategies and perspectives to improve the translational progress are suggested. Despite these challenges, we are optimistic that LPA blockage, particularly in combination with other agents, is on the horizon to be incorporated into clinical applications.",
keywords = "Autotaxin (ATX), Cancer stem cell (CSC), Electrospray ionization tandem mass spectrometry (ESI-MS/MS), G-protein coupled receptor (GPCR), Lipid phosphate phosphatase enzymes (LPPs), Lysophosphatidic acid (LPA), Nuclear receptor peroxisome proliferator-activated receptor (PPAR), Ovarian cancer (OC), Phospholipase A enzymes (PLAs), Sphingosine-1 phosphate (S1P)",
author = "Yan Xu",
year = "2019",
month = "10",
doi = "10.3390/cancers11101523",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

TY - JOUR

T1 - Targeting lysophosphatidic acid in cancer

T2 - The issues in moving from bench to bedside

AU - Xu, Yan

PY - 2019/10

Y1 - 2019/10

N2 - Since the clear demonstration of lysophosphatidic acid (LPA)’s pathological roles in cancer in the mid-1990s, more than 1000 papers relating LPA to various types of cancer were published. Through these studies, LPA was established as a target for cancer. Although LPA-related inhibitors entered clinical trials for fibrosis, the concept of targeting LPA is yet to be moved to clinical cancer treatment. The major challenges that we are facing in moving LPA application from bench to bedside include the intrinsic and complicated metabolic, functional, and signaling properties of LPA, as well as technical issues, which are discussed in this review. Potential strategies and perspectives to improve the translational progress are suggested. Despite these challenges, we are optimistic that LPA blockage, particularly in combination with other agents, is on the horizon to be incorporated into clinical applications.

AB - Since the clear demonstration of lysophosphatidic acid (LPA)’s pathological roles in cancer in the mid-1990s, more than 1000 papers relating LPA to various types of cancer were published. Through these studies, LPA was established as a target for cancer. Although LPA-related inhibitors entered clinical trials for fibrosis, the concept of targeting LPA is yet to be moved to clinical cancer treatment. The major challenges that we are facing in moving LPA application from bench to bedside include the intrinsic and complicated metabolic, functional, and signaling properties of LPA, as well as technical issues, which are discussed in this review. Potential strategies and perspectives to improve the translational progress are suggested. Despite these challenges, we are optimistic that LPA blockage, particularly in combination with other agents, is on the horizon to be incorporated into clinical applications.

KW - Autotaxin (ATX)

KW - Cancer stem cell (CSC)

KW - Electrospray ionization tandem mass spectrometry (ESI-MS/MS)

KW - G-protein coupled receptor (GPCR)

KW - Lipid phosphate phosphatase enzymes (LPPs)

KW - Lysophosphatidic acid (LPA)

KW - Nuclear receptor peroxisome proliferator-activated receptor (PPAR)

KW - Ovarian cancer (OC)

KW - Phospholipase A enzymes (PLAs)

KW - Sphingosine-1 phosphate (S1P)

UR - http://www.scopus.com/inward/record.url?scp=85073728157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073728157&partnerID=8YFLogxK

U2 - 10.3390/cancers11101523

DO - 10.3390/cancers11101523

M3 - Review article

AN - SCOPUS:85073728157

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 10

M1 - 1523

ER -